Navigation Links
NanoBio Corporation Raises $12 Million in Series B Financing
Date:2/18/2009

ANN ARBOR, Mich., Feb. 18 /PRNewswire/ -- NanoBio Corp., a biopharmaceutical company developing dermatological products, anti-infective treatments and intranasal vaccines, announced today that it has acquired $12 million in series B equity financing with Perseus LLC and other existing investors. To date, over $80 million in funding has been directed toward the development of the company's NanoStat(TM) technology platform.

The series B funding will be used by the company to complete a phase 1 study investigating a novel topical treatment for acne, preclinical studies on a nebulized therapy for cystic fibrosis, and a phase 1 study for an intranasal seasonal influenza vaccine.

This funding follows several recent product announcements by NanoBio, including:

-- Phase 2b data indicating that the company's topical herpes labialis product speeds healing as effectively as the leading oral systemic drugs but without safety or toxicity concerns

-- Preclinical data demonstrating that the company's novel nanoemulsion technology kills highly resistant bacteria found in patients with cystic fibrosis

-- Preclinical data indicating that a single administration of NanoBio's novel intranasal influenza vaccine elicits immune responses in ferrets more than 20 times higher than those generated by two injections of currently approved vaccines

"We are pleased with the continued, strong support of Perseus and the company's other investors," said James R. Baker Jr., M.D., founder and chairman of NanoBio Corp. "Based upon the strength of our recent data and our future development plans, there was significant interest from investors with respect to participating in this financing despite the challenging economic conditions."

About NanoBio

NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.


'/>"/>
SOURCE NanoBio Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NanoBio to Give Four Scientific Presentations at Upcoming National Meeting of Pharmaceutical Scientists
2. NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008
3. Daniel B. Dubin, M.D., Joins NanoBio Corp.s Board of Directors
4. FierceBiotech Names NanoBio Corporation as One of the Fierce 15 Biotech Companies of 2008
5. David M. Stout Joins NanoBio Corporations Board of Directors
6. Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research
7. NanoBio Expands Drug Development Team for Its Anti-Infective Products
8. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Monoplace Hyperbaric Chambers
9. Newbridge Securities Corporation Forms BioVentures Division
10. Volcano Corporation Presentation at Roth Capital Partners Conference to Be Webcast
11. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Ky. , Feb. 10, 2016 NX ... utilizing its proprietary NeXosome® technology for early warning ... of its most recent study by Dr. ... at the Society for Maternal Fetal Medicine,s (SMFM) annual ... GA, February 1-6 th , 2016.  The presentation reported ...
(Date:2/10/2016)... York, New York (PRWEB) , ... ... ... Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has joined the Human ... and immunotherapies for infectious diseases and cancer. , The Human Vaccines ...
(Date:2/10/2016)... plc (NYSE: AGN ) a leading global pharmaceutical ... CEO and President, will be featured as the keynote ... Capital Markets Healthcare Conference on Tuesday, February 23, 2016 ... Hotel in New York, NY . ... accessed on Allergan,s Investor Relations web site at ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a ... promotion of two long-standing principal investigators (PI) to the roles of Chief Medical ... Development. , Dr. Laurence Chu, a Benchmark Research PI in the Austin office, ...
Breaking Biology Technology:
(Date:1/22/2016)... DUBLIN , January 22, 2016 ... has announced the addition of the  ... to their offering. --> ... of the  "Global Behavioral Biometric Market ... --> Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ...
(Date:1/20/2016)... , Jan. 20, 2016 A market ... to directly benefit from the explosion in genomics knowledge. ... Howe Sound Research. A range of dynamic trends are ... - personalized medicine - pharmacogenomics - pathogen evolution ... with large markets - greater understanding of the role ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., ... that simplifies the use and access of ubiquitous ... go-to-market partnership with American Cyber.  ... extensive experience leading transformational C4ISR and Cyber initiatives ... integrating the latest proven technology solutions," said ...
Breaking Biology News(10 mins):